Search

Displaying results 1671 - 1680 of 5079 in total
  1. Drug

    Eldecalcitol

    go.drugbank.com/drugs/DB05295
    Investigational

    Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. … Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation.

    Categories: Vitamin D and Analogues
  2. Drug

    Mecobalamin

    go.drugbank.com/drugs/DB03614
    ApprovedInvestigational

    Mixtures: Levomefolate Calcium, Pyridoxal 5-phosphate, Methylcobalamin and Schizochytrium DHA Oil
  3. Drug

    Hydroflumethiazide

    go.drugbank.com/drugs/DB00774
    ApprovedWithdrawn

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)

  4. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inop...

  5. Drug

    Chymotrypsin

    go.drugbank.com/drugs/DB09375
    ApprovedInvestigationalVet approvedWithdrawn

    Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. Like most pr...

  6. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular

  7. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due

  8. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction. During sexual stimulation, nitric oxide (NO) is released...

  9. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia ...

  10. Drug

    Equine Botulinum Neurotoxin A Immune FAB2

    go.drugbank.com/drugs/DB13900
    Approved

    Equine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A. It is intravenously administered for the treat...